Experimenter-defined quit dates for smoking cessation: Adherence improves outcomes for women but not for men

Belinda Borrelli, George Papandonatos, Bonnie Spring, Brian Hitsman, Raymond Niaura

Research output: Contribution to journalArticle

Abstract

Aims: Smoking cessation treatment trials often require that smokers quit on or before a protocol-defined date. The goals of this paper were to: (1) identify factors associated with adherence to a protocol-defined quit date and (2) determine whether such adherence predicts cessation outcome (relapse). Design: A quasi-experimental secondary analysis of data collected from a randomized placebo-controlled trial of fluoxetine (60 mg or 30 mg) versus placebo for smoking cessation. Setting and participants: Clinic-based smoking cessation treatment program comprising 989 non-depressed smokers. Intervention: Participants received cognitive behavioral therapy for smoking cessation and either study medication or placebo for 10 weeks. They were required to set a quit date within 2 weeks of their second study visit (by visit 4). Findings Significant predictors of quit date adherence were low nicotine dependence and active drug treatment. High-dose fluoxetine (60 mg) and male gender were protective against relapse. Adherence to quit date was not an independent predictor of relapse; instead there was a significant interaction between quit date adherence and gender. Among non-adherers to the quit date, women were more than 2.5 times as likely as men to relapse; among adherers to the quit date, women were only 1.3 times as likely as men to relapse. Conclusions: Although women were more likely than men to relapse regardless of quit date adherence, adherence was strongly protective against relapse for women.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalAddiction
Volume99
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Smoking Cessation
Recurrence
Withholding Treatment
Fluoxetine
Placebos
Tobacco Use Disorder
Cognitive Therapy
Randomized Controlled Trials
Pharmaceutical Preparations

Keywords

  • Fluoxetine
  • Quit attempts
  • Relapse
  • Smoking cessation

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Experimenter-defined quit dates for smoking cessation : Adherence improves outcomes for women but not for men. / Borrelli, Belinda; Papandonatos, George; Spring, Bonnie; Hitsman, Brian; Niaura, Raymond.

In: Addiction, Vol. 99, No. 3, 03.2004, p. 378-385.

Research output: Contribution to journalArticle

Borrelli, Belinda ; Papandonatos, George ; Spring, Bonnie ; Hitsman, Brian ; Niaura, Raymond. / Experimenter-defined quit dates for smoking cessation : Adherence improves outcomes for women but not for men. In: Addiction. 2004 ; Vol. 99, No. 3. pp. 378-385.
@article{4d2701d5488147a2ac3109bf6dd4ecbb,
title = "Experimenter-defined quit dates for smoking cessation: Adherence improves outcomes for women but not for men",
abstract = "Aims: Smoking cessation treatment trials often require that smokers quit on or before a protocol-defined date. The goals of this paper were to: (1) identify factors associated with adherence to a protocol-defined quit date and (2) determine whether such adherence predicts cessation outcome (relapse). Design: A quasi-experimental secondary analysis of data collected from a randomized placebo-controlled trial of fluoxetine (60 mg or 30 mg) versus placebo for smoking cessation. Setting and participants: Clinic-based smoking cessation treatment program comprising 989 non-depressed smokers. Intervention: Participants received cognitive behavioral therapy for smoking cessation and either study medication or placebo for 10 weeks. They were required to set a quit date within 2 weeks of their second study visit (by visit 4). Findings Significant predictors of quit date adherence were low nicotine dependence and active drug treatment. High-dose fluoxetine (60 mg) and male gender were protective against relapse. Adherence to quit date was not an independent predictor of relapse; instead there was a significant interaction between quit date adherence and gender. Among non-adherers to the quit date, women were more than 2.5 times as likely as men to relapse; among adherers to the quit date, women were only 1.3 times as likely as men to relapse. Conclusions: Although women were more likely than men to relapse regardless of quit date adherence, adherence was strongly protective against relapse for women.",
keywords = "Fluoxetine, Quit attempts, Relapse, Smoking cessation",
author = "Belinda Borrelli and George Papandonatos and Bonnie Spring and Brian Hitsman and Raymond Niaura",
year = "2004",
month = "3",
doi = "10.1111/j.1360-0443.2004.00648.x",
language = "English (US)",
volume = "99",
pages = "378--385",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Experimenter-defined quit dates for smoking cessation

T2 - Adherence improves outcomes for women but not for men

AU - Borrelli, Belinda

AU - Papandonatos, George

AU - Spring, Bonnie

AU - Hitsman, Brian

AU - Niaura, Raymond

PY - 2004/3

Y1 - 2004/3

N2 - Aims: Smoking cessation treatment trials often require that smokers quit on or before a protocol-defined date. The goals of this paper were to: (1) identify factors associated with adherence to a protocol-defined quit date and (2) determine whether such adherence predicts cessation outcome (relapse). Design: A quasi-experimental secondary analysis of data collected from a randomized placebo-controlled trial of fluoxetine (60 mg or 30 mg) versus placebo for smoking cessation. Setting and participants: Clinic-based smoking cessation treatment program comprising 989 non-depressed smokers. Intervention: Participants received cognitive behavioral therapy for smoking cessation and either study medication or placebo for 10 weeks. They were required to set a quit date within 2 weeks of their second study visit (by visit 4). Findings Significant predictors of quit date adherence were low nicotine dependence and active drug treatment. High-dose fluoxetine (60 mg) and male gender were protective against relapse. Adherence to quit date was not an independent predictor of relapse; instead there was a significant interaction between quit date adherence and gender. Among non-adherers to the quit date, women were more than 2.5 times as likely as men to relapse; among adherers to the quit date, women were only 1.3 times as likely as men to relapse. Conclusions: Although women were more likely than men to relapse regardless of quit date adherence, adherence was strongly protective against relapse for women.

AB - Aims: Smoking cessation treatment trials often require that smokers quit on or before a protocol-defined date. The goals of this paper were to: (1) identify factors associated with adherence to a protocol-defined quit date and (2) determine whether such adherence predicts cessation outcome (relapse). Design: A quasi-experimental secondary analysis of data collected from a randomized placebo-controlled trial of fluoxetine (60 mg or 30 mg) versus placebo for smoking cessation. Setting and participants: Clinic-based smoking cessation treatment program comprising 989 non-depressed smokers. Intervention: Participants received cognitive behavioral therapy for smoking cessation and either study medication or placebo for 10 weeks. They were required to set a quit date within 2 weeks of their second study visit (by visit 4). Findings Significant predictors of quit date adherence were low nicotine dependence and active drug treatment. High-dose fluoxetine (60 mg) and male gender were protective against relapse. Adherence to quit date was not an independent predictor of relapse; instead there was a significant interaction between quit date adherence and gender. Among non-adherers to the quit date, women were more than 2.5 times as likely as men to relapse; among adherers to the quit date, women were only 1.3 times as likely as men to relapse. Conclusions: Although women were more likely than men to relapse regardless of quit date adherence, adherence was strongly protective against relapse for women.

KW - Fluoxetine

KW - Quit attempts

KW - Relapse

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=1542511720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542511720&partnerID=8YFLogxK

U2 - 10.1111/j.1360-0443.2004.00648.x

DO - 10.1111/j.1360-0443.2004.00648.x

M3 - Article

C2 - 14982551

AN - SCOPUS:1542511720

VL - 99

SP - 378

EP - 385

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 3

ER -